Advertisement

Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)

      In translational models of pulmonary arterial hypertension (PAH), spironolactone improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type-B receptor function in pulmonary endothelial cells. This observation suggests that coupling spironolactone with inhibition of endothelin type-A receptor–mediated pulmonary vasoconstriction may be a useful treatment strategy for patients with PAH. We examined clinical data from patients randomized to placebo or the selective endothelin type-A receptor antagonist ambrisentan (10 mg/day) and in whom spironolactone use was reported during ARIES-1 and -2, which were randomized, double-blind, placebo-controlled trials assessing the effect of ambrisentan for 12 weeks on clinical outcome in PAH. From patients randomized to placebo (n = 132) or ambrisentan (n = 67), we identified concurrent spironolactone use in 21 (15.9%) and 10 (14.9%) patients, respectively. Compared with patients treated with ambrisentan alone (n = 57), therapy with ambrisentan + spironolactone improved change in 6-minute walk distance by 94% at week 12 (mean ± SE, +38.2 ± 8.1 vs +74.2 ± 27.4 m, p = 0.11), improved plasma B-type natriuretic peptide concentration by 1.7-fold (p = 0.08), and resulted in a 90% relative increase in the number of patients improving ≥1 World Health Organization functional class (p = 0.08). Progressive illness, PAH-associated hospitalizations, or death occurred as an end point for 5.3% of ambrisentan-treated patients; however, no patient treated with ambrisentan + spironolactone reached any of these end points. In conclusion, these pilot data suggest that coupling spironolactone and endothelin type-A receptor antagonism may be clinically beneficial in PAH. Prospective clinical trials are required to further characterize our findings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maron B.A.
        • Opotowsky A.R.
        • Landzberg M.J.
        • Loscalzo J.
        • Waxman A.B.
        • Leopold J.A.
        Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.
        Eur J Heart Fail. 2013; 15: 277-283
        • De Man F.S.
        • Tu L.
        • Handoko M.L.
        • Rain S.
        • Ruiter G.
        • François C.
        • Schalij I.
        • Dorfmüller P.
        • Simmoneau G.
        • Fadel E.
        • Perros F.
        • Boonstra A.
        • Postmus P.E.
        • van der Velden J.
        • Vonk-Noordegraaf A.
        • Humbert M.
        • Eddahibi S.
        • Guignabert C.
        Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.
        Am J Respir Crit Care Med. 2012; 186: 780-790
        • Martyniuk T.V.
        • Chazova I.E.
        • Masenko V.P.
        • Volkov V.N.
        • Belenkov Iu N.
        [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension].
        Ter Arkh. 1998; 70: 33-36
        • Bansal S.
        • Badesch D.
        • Bull T.
        • Schrier R.W.
        Role of vasopressin and aldosterone in pulmonary arterial hypertension: a pilot study.
        Contemp Clin Trials. 2009; 30: 392-399
        • Elinoff J.M.
        • Rame J.E.
        • Forfia P.R.
        • Hall M.K.
        • Sun J.
        • Gharib A.
        • Abd-Elmoniem K.
        • Graninger G.
        • Harper B.
        • Danner R.L.
        • Solomon M.A.
        A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
        Trials. 2013; (Epub ahead of print)
        • Maron B.A.
        • Zhang Y.-Y.
        • White K.
        • Chan S.Y.
        • Handy D.E.
        • Mahoney C.E.
        • Loscalzo J.
        • Leopold J.A.
        Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
        Circulation. 2012; 126: 963-974
        • Galiè N.
        • Olschewski H.
        • Oudiz R.J.
        • Torres F.
        • Frost A.
        • Ghofrani H.A.
        • Badesch D.B.
        • McGoon M.D.
        • McLaughlin V.V.
        • Roecker E.B.
        • Gerber M.J.
        • Dufton C.
        • Wiens B.L.
        • Rubin L.J.
        Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Study 1 and 2.
        Circulation. 2008; 117: 3010-3019
        • Shapiro S.
        • Pollock D.M.
        • Gillies H.
        • Henig N.
        • Allard M.
        • Blair C.
        • Anglen C.
        • Kohan D.E.
        Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
        Am J Cardiol. 2012; 110: 1373-1377
        • Galié N.
        • Badesch D.
        • Oudiz R.
        • Simonneau G.
        • McGoon M.D.
        • Keogh A.M.
        • Frost A.E.
        • Zwicke D.
        • Naeije R.
        • Shapiro S.
        • Olschewski H.
        • Rubin L.J.
        Ambrisentan therapy for pulmonary arterial hypertension.
        J Am Coll Cardiol. 2005; 46: 529-535
        • Piao L.
        • Fang Y.H.
        • Parikh K.S.
        • Ryan J.J.
        • D’Souza K.M.
        • Theccanat T.
        • Toth P.T.
        • Pogoriler J.
        • Paul J.
        • Blaxall B.C.
        • Akhter S.A.
        • Archer S.L.
        GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.
        Circulation. 2012; 126: 2859-2869
        • White K.
        • Johansen A.K.
        • Nilsen M.
        • Ciuclan L.
        • Wallace E.
        • Paton L.
        • Campbell A.
        • Morecroft I.
        • Loughlin I.
        • McClure J.D.
        • Thomas M.
        • Mair K.M.
        • MacLean M.R.
        Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.
        Circulation. 2012; 126: 1087-1098
        • Preston I.R.
        • Sagliani K.D.
        • Warburton R.R.
        • Hill N.S.
        • Fanburg B.L.
        • Jaffe I.Z.
        Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
        Am J Physiol Lung Cell Mol Physiol. 2013; (Mar 1: Epub ahead of print)
        • Kokubu T.
        • Kazatani Y.
        • Hamada M.
        • Matsuzaki K.
        • Ito T.
        • Nishimura K.
        • Ochi T.
        • Daimon F.
        • Joh T.
        Is captopril effective in primary pulmonary hypertension?.
        Circ J. 1982; 46: 1095-1097
        • Rubin L.J.
        • Badesch D.B.
        • Barst R.J.
        • Galie N.
        • Black C.M.
        • Keogh A.
        • Pulido T.
        • Frost A.
        • Roux S.
        • Leconte I.
        • Landzberg M.
        • Simmoneau G.
        Bosentan therapy for pulmonary arterial hypertension.
        N Eng J Med. 2002; 346: 896-903
        • McLaughlin W.
        • Archer S.L.
        • Badesch D.B.
        • Barst R.J.
        • Farber H.W.
        • Lindner J.R.
        • Mathier M.A.
        • McGoon M.D.
        • Park M.H.
        • Rosenson R.S.
        • Rubin L.J.
        • Tapson V.F.
        • Varga J.
        • American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association
        ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association.
        J Am Coll Cardiol. 2009; 53: 1573-1619
        • Pui-Sze So P.
        • Davies R.A.
        • Chandy G.
        • Stewart D.
        • Beanlands R.S.B.
        • Haddad H.
        • Pugliese C.
        • Mielniczuk L.M.
        Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.
        Am J Cardiol. 2012; 109: 1504-1509
        • Cabrol S.
        • Souza R.
        • Jais X.
        • Fadel E.
        • Ali R.H.
        • Humbert M.
        • Dartevelle P.
        • Simonneau G.
        • Sitbon O.
        Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
        J Heart Lung Transplant. 2007; 26: 357-362
        • Kirshnan U.
        • Takatsuki S.
        • Ivy D.D.
        • Kerstein J.
        • Calderbank M.
        • Coleman E.
        • Rosenzweig E.B.
        Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
        Am J Cardiol. 2012; 110: 1704-1709
        • Miyamichi-Yamamoto S.
        • Fukumoto Y.
        • Sugimura K.
        • Ishii T.
        • Satoh K.
        • Milura Y.
        • Tatebe S.
        • Nochioka K.
        • Aoki T.
        • Do E.Z.
        • Shimokawa H.
        Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disorder.
        Circ J. 2011; 75: 2668-2674
        • Juurlink D.N.
        • Mamdani M.M.
        • Lee D.S.
        • Kopp A.
        • Austin P.C.
        • Laupacis A.
        • Redelmeier D.A.
        Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
        N Eng J Med. 2004; 351: 543-551
        • Maron B.A.
        • Leopold J.A.
        Aldosterone receptor antagonists: effective but often forgotten.
        Circulation. 2010; 121: 934-939